메뉴 건너뛰기




Volumn 14, Issue 2, 2012, Pages

Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; HLA B27 ANTIGEN; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

EID: 84859107751     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3766     Document Type: Article
Times cited : (30)

References (45)
  • 3
    • 33745894976 scopus 로고    scopus 로고
    • ATLAS Study Group: efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial
    • 10.1002/art.21913, 16802350
    • van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC. ATLAS Study Group: efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:2136-2146. 10.1002/art.21913, 16802350.
    • (2006) Arthritis Rheum , vol.54 , pp. 2136-2146
    • van der Heijde, D.1    Kivitz, A.2    Schiff, M.H.3    Sieper, J.4    Dijkmans, B.A.5    Braun, J.6    Dougados, M.7    Reveille, J.D.8    Wong, R.L.9    Kupper, H.10    Davis, J.C.11
  • 4
    • 26844432745 scopus 로고    scopus 로고
    • Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-bind, randomized, placebo-controlled trial
    • 10.1002/art.21306, 16200601, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group
    • Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA, . Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-bind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:3279-3289. 10.1002/art.21306, 16200601, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group.
    • (2005) Arthritis Rheum , vol.52 , pp. 3279-3289
    • Mease, P.J.1    Gladman, D.D.2    Ritchlin, C.T.3    Ruderman, E.M.4    Steinfeld, S.D.5    Choy, E.H.6    Sharp, J.T.7    Ory, P.A.8    Perdok, R.J.9    Weinberg, M.A.10
  • 5
    • 19044382942 scopus 로고    scopus 로고
    • Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
    • 10.1136/ard.2004.032268, 1755609, 15677701
    • Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150-1157. 10.1136/ard.2004.032268, 1755609, 15677701.
    • (2005) Ann Rheum Dis , vol.64 , pp. 1150-1157
    • Antoni, C.1    Krueger, G.G.2    de Vlam, K.3    Birbara, C.4    Beutler, A.5    Guzzo, C.6
  • 6
    • 0034729950 scopus 로고    scopus 로고
    • Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
    • 10.1016/S0140-6736(00)02530-7, 10972371
    • Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390. 10.1016/S0140-6736(00)02530-7, 10972371.
    • (2000) Lancet , vol.356 , pp. 385-390
    • Mease, P.J.1    Goffe, B.S.2    Metz, J.3    VanderStoep, A.4    Finck, B.5    Burge, D.J.6
  • 7
    • 79551658174 scopus 로고    scopus 로고
    • Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry
    • 10.1002/art.30117, 21279995
    • Glintborg B, Østergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, Rifbjerg-Madsen S, Lorenzen T, Hetland ML. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011, 63:382-390. 10.1002/art.30117, 21279995.
    • (2011) Arthritis Rheum , vol.63 , pp. 382-390
    • Glintborg, B.1    Østergaard, M.2    Dreyer, L.3    Krogh, N.S.4    Tarp, U.5    Hansen, M.S.6    Rifbjerg-Madsen, S.7    Lorenzen, T.8    Hetland, M.L.9
  • 8
    • 78149479826 scopus 로고    scopus 로고
    • Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry
    • 10.1136/ard.2009.124446, 20511613
    • Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010, 69:2002-2008. 10.1136/ard.2009.124446, 20511613.
    • (2010) Ann Rheum Dis , vol.69 , pp. 2002-2008
    • Glintborg, B.1    Ostergaard, M.2    Krogh, N.S.3    Dreyer, L.4    Kristensen, H.L.5    Hetland, M.L.6
  • 9
    • 54349109184 scopus 로고    scopus 로고
    • Successful treatment of psoriatic arthritis with rituximab
    • Cohen JD. Successful treatment of psoriatic arthritis with rituximab. Ann Rheum Dis 2008, 67:1647-1348.
    • (2008) Ann Rheum Dis , vol.67 , pp. 1647-11348
    • Cohen, J.D.1
  • 10
    • 54449096535 scopus 로고    scopus 로고
    • The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B
    • Rodríguez-Escalera C, Fernández-Nebro A. The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. Rheumatology (Oxford) 2008, 47:1732-1733.
    • (2008) Rheumatology (Oxford) , vol.47 , pp. 1732-1733
    • Rodríguez-Escalera, C.1    Fernández-Nebro, A.2
  • 11
    • 77951608958 scopus 로고    scopus 로고
    • Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis
    • 10.1136/ard.2009.113233, 19700394
    • Cañete JD, Celis R, Hernández V, Pablos JL, Sanmartí R. Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann Rheum Dis 2010, 69:935-936. 10.1136/ard.2009.113233, 19700394.
    • (2010) Ann Rheum Dis , vol.69 , pp. 935-936
    • Cañete, J.D.1    Celis, R.2    Hernández, V.3    Pablos, J.L.4    Sanmartí, R.5
  • 12
    • 77951025652 scopus 로고    scopus 로고
    • Abatacept as an option therapy in difficult to treat psoriatic arthritis
    • 10.1007/s00296-009-1041-1, 19579026
    • Vieira FJ, Callado MR, Vieira WP. Abatacept as an option therapy in difficult to treat psoriatic arthritis. Rheumatol Int 2010, 30:849-850. 10.1007/s00296-009-1041-1, 19579026.
    • (2010) Rheumatol Int , vol.30 , pp. 849-850
    • Vieira, F.J.1    Callado, M.R.2    Vieira, W.P.3
  • 14
    • 46449083444 scopus 로고    scopus 로고
    • Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis
    • 10.1016/j.jbspin.2008.01.023, 18457981
    • Wendling D, Augé B, Streit G, Toussirot E, Mathieu S. Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis. Joint Bone Spine 2008, 75:510-511. 10.1016/j.jbspin.2008.01.023, 18457981.
    • (2008) Joint Bone Spine , vol.75 , pp. 510-511
    • Wendling, D.1    Augé, B.2    Streit, G.3    Toussirot, E.4    Mathieu, S.5
  • 15
    • 77951757221 scopus 로고    scopus 로고
    • Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial
    • 10.1002/art.27383, 20461780
    • Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010, 62:1290-1297. 10.1002/art.27383, 20461780.
    • (2010) Arthritis Rheum , vol.62 , pp. 1290-1297
    • Song, I.H.1    Heldmann, F.2    Rudwaleit, M.3    Listing, J.4    Appel, H.5    Braun, J.6    Sieper, J.7
  • 16
    • 75749112924 scopus 로고    scopus 로고
    • Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry
    • 10.1136/ard.2008.107102, 20107035
    • Nocturne G, Dougados M, Constantin A, Richez C, Sellam J, Simon A, Wendling D, Mariette X, Gottenberg JE. Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry. Ann Rheum Dis 2010, 69:471-472. 10.1136/ard.2008.107102, 20107035.
    • (2010) Ann Rheum Dis , vol.69 , pp. 471-472
    • Nocturne, G.1    Dougados, M.2    Constantin, A.3    Richez, C.4    Sellam, J.5    Simon, A.6    Wendling, D.7    Mariette, X.8    Gottenberg, J.E.9
  • 17
    • 79955868460 scopus 로고    scopus 로고
    • Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study
    • 10.1136/ard.2010.145946, 21415053
    • Song IH, Heldmann F, Rudwaleit M, Haibel H, Weiß A, Braun J, Sieper J. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011, 70:1108-1110. 10.1136/ard.2010.145946, 21415053.
    • (2011) Ann Rheum Dis , vol.70 , pp. 1108-1110
    • Song, I.H.1    Heldmann, F.2    Rudwaleit, M.3    Haibel, H.4    Weiß, A.5    Braun, J.6    Sieper, J.7
  • 19
    • 0027943397 scopus 로고
    • Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity
    • 10.1093/rheumatology/33.10.927, 7921752
    • Gratacós J, Collado A, Filella X, Sanmartí R, Cañete J, Llena J, Molina R, Ballesta A, Muñoz-Gómez J. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994, 33:927-931. 10.1093/rheumatology/33.10.927, 7921752.
    • (1994) Br J Rheumatol , vol.33 , pp. 927-931
    • Gratacós, J.1    Collado, A.2    Filella, X.3    Sanmartí, R.4    Cañete, J.5    Llena, J.6    Molina, R.7    Ballesta, A.8    Muñoz-Gómez, J.9
  • 20
    • 0028341585 scopus 로고
    • Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis
    • 1005360, 8037502
    • Tutuncu ZN, Bilgie A, Kennedy LG, Calin A. Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis. Ann Rheum Dis 1994, 53:425-426. 1005360, 8037502.
    • (1994) Ann Rheum Dis , vol.53 , pp. 425-426
    • Tutuncu, Z.N.1    Bilgie, A.2    Kennedy, L.G.3    Calin, A.4
  • 21
    • 0030757087 scopus 로고    scopus 로고
    • A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies
    • 10.1093/rheumatology/36.3.400, 9156766
    • Claudepierre P, Rymer JC, Authier FJ, Allanore Y, Larget-Piet B, Gherardi R, Chevalier X. A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies. Br J Rheumatol 1997, 36:400-401. 10.1093/rheumatology/36.3.400, 9156766.
    • (1997) Br J Rheumatol , vol.36 , pp. 400-401
    • Claudepierre, P.1    Rymer, J.C.2    Authier, F.J.3    Allanore, Y.4    Larget-Piet, B.5    Gherardi, R.6    Chevalier, X.7
  • 22
    • 63049139677 scopus 로고    scopus 로고
    • Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?
    • Alenius GM, Eriksson C, Rantapää Dahlqvist S. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?. Clin Exp Rheumatol 2009, 27:120-123.
    • (2009) Clin Exp Rheumatol , vol.27 , pp. 120-123
    • Alenius, G.M.1    Eriksson, C.2    Rantapää Dahlqvist, S.3
  • 23
    • 33744486334 scopus 로고    scopus 로고
    • Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases
    • 10.1136/ard.2005.037465, 1798185, 16249231
    • François RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 2006, 65:713-720. 10.1136/ard.2005.037465, 1798185, 16249231.
    • (2006) Ann Rheum Dis , vol.65 , pp. 713-720
    • François, R.J.1    Neure, L.2    Sieper, J.3    Braun, J.4
  • 24
    • 70349402169 scopus 로고    scopus 로고
    • Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
    • 10.1136/ard.2008.092866, 2732899, 19019888
    • Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009, 68:1580-1584. 10.1136/ard.2008.092866, 2732899, 19019888.
    • (2009) Ann Rheum Dis , vol.68 , pp. 1580-1584
    • Nishimoto, N.1    Miyasaka, N.2    Yamamoto, K.3    Kawai, S.4    Takeuchi, T.5    Azuma, J.6
  • 25
    • 0030476890 scopus 로고    scopus 로고
    • Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy
    • 10.1093/rheumatology/35.12.1330, 9010072
    • Wendling D, Racadot E, Toussirot E, Wijdenes J. Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy. Br J Rheumatol 1996, 35:1330. 10.1093/rheumatology/35.12.1330, 9010072.
    • (1996) Br J Rheumatol , vol.35 , pp. 1330
    • Wendling, D.1    Racadot, E.2    Toussirot, E.3    Wijdenes, J.4
  • 26
    • 78649907237 scopus 로고    scopus 로고
    • Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists
    • 10.1016/j.jbspin.2010.08.004, 20851032
    • Brulhart L, Nissen MJ, Chevallier P, Gabay C. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine 2010, 77:625-626. 10.1016/j.jbspin.2010.08.004, 20851032.
    • (2010) Joint Bone Spine , vol.77 , pp. 625-626
    • Brulhart, L.1    Nissen, M.J.2    Chevallier, P.3    Gabay, C.4
  • 28
    • 78049418460 scopus 로고    scopus 로고
    • Mixed response to tocilizumab for ankylosing spondylitis
    • 10.1136/ard.2009.126706, 20525837
    • Henes JC, Horger M, Guenaydin I, Kanz L, Koetter I. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis 2010, 69:2217-2218. 10.1136/ard.2009.126706, 20525837.
    • (2010) Ann Rheum Dis , vol.69 , pp. 2217-2218
    • Henes, J.C.1    Horger, M.2    Guenaydin, I.3    Kanz, L.4    Koetter, I.5
  • 29
    • 78649904087 scopus 로고    scopus 로고
    • Short-term effect of IL-6 inhibition in spondylarthritis
    • 10.1016/j.jbspin.2010.09.011, 20971669
    • Wendling D, Bossert M, Prati C. Short-term effect of IL-6 inhibition in spondylarthritis. Joint Bone Spine 2010, 77:624-625. 10.1016/j.jbspin.2010.09.011, 20971669.
    • (2010) Joint Bone Spine , vol.77 , pp. 624-625
    • Wendling, D.1    Bossert, M.2    Prati, C.3
  • 30
    • 20344381320 scopus 로고    scopus 로고
    • The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody
    • 10.1517/14712598.5.5.683, 15934843
    • Mihara M, Nishimoto N, Ohsugi Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 2005, 5:683-690. 10.1517/14712598.5.5.683, 15934843.
    • (2005) Expert Opin Biol Ther , vol.5 , pp. 683-690
    • Mihara, M.1    Nishimoto, N.2    Ohsugi, Y.3
  • 31
    • 84859100471 scopus 로고    scopus 로고
    • Club Rhumatismes et Inflammation
    • Club Rhumatismes et Inflammation. , http://www.cri-net.com
  • 34
    • 0021272107 scopus 로고
    • Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria
    • 10.1002/art.1780270401, 6231933
    • van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368. 10.1002/art.1780270401, 6231933.
    • (1984) Arthritis Rheum , vol.27 , pp. 361-368
    • van der Linden, S.1    Valkenburg, H.A.2    Cats, A.3
  • 35
    • 0025377351 scopus 로고
    • Criteria of the classification of spondylarthropathies
    • Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic 1990, 57:85-89.
    • (1990) Rev Rhum Mal Osteoartic , vol.57 , pp. 85-89
    • Amor, B.1    Dougados, M.2    Mijiyawa, M.3
  • 37
    • 33746951437 scopus 로고    scopus 로고
    • Classification criteria for psoriatic arthritis: development of new criteria from a large international study
    • 10.1002/art.21972, 16871531, CASPAR Study Group
    • Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, . CASPAR Study Group Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665-2673. 10.1002/art.21972, 16871531, CASPAR Study Group.
    • (2006) Arthritis Rheum , vol.54 , pp. 2665-2673
    • Taylor, W.1    Gladman, D.2    Helliwell, P.3    Marchesoni, A.4    Mease, P.5    Mielants, H.6
  • 38
    • 33144469246 scopus 로고    scopus 로고
    • First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
    • 10.1136/ard.2005.040758, 1798064, 16096329, ASAS Working Group
    • Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D, . ASAS Working Group First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006, 65:316-320. 10.1136/ard.2005.040758, 1798064, 16096329, ASAS Working Group.
    • (2006) Ann Rheum Dis , vol.65 , pp. 316-320
    • Braun, J.1    Davis, J.2    Dougados, M.3    Sieper, J.4    van der Linden, S.5    van der Heijde, D.6
  • 39
    • 84855674874 scopus 로고    scopus 로고
    • Tocilizumab in axial spondylarthritis: about 18 cases
    • 10.1136/ard.2010.132662, 21062853
    • Dudler J, Aubry-Rozier B. Tocilizumab in axial spondylarthritis: about 18 cases. Ann Rheum Dis 2011, 70:128. 10.1136/ard.2010.132662, 21062853.
    • (2011) Ann Rheum Dis , vol.70 , pp. 128
    • Dudler, J.1    Aubry-Rozier, B.2
  • 41
    • 77955001179 scopus 로고    scopus 로고
    • Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis
    • 10.1136/ard.2010.129148, 20498200
    • Hayer S, Niederreiter B, Nagelreiter I, Smolen J, Redlich K. Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis. Ann Rheum Dis 2010, 69:1403-1406. 10.1136/ard.2010.129148, 20498200.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1403-1406
    • Hayer, S.1    Niederreiter, B.2    Nagelreiter, I.3    Smolen, J.4    Redlich, K.5
  • 43
    • 13244279795 scopus 로고    scopus 로고
    • Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
    • 10.1136/ard.2004.023176, 1755331, 15208175
    • Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005, 64:296-298. 10.1136/ard.2004.023176, 1755331, 15208175.
    • (2005) Ann Rheum Dis , vol.64 , pp. 296-298
    • Haibel, H.1    Rudwaleit, M.2    Listing, J.3    Sieper, J.4
  • 44
    • 79952113703 scopus 로고    scopus 로고
    • An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX)
    • 10.1007/s10067-010-1504-5, 20532937
    • Jung N, Hellmann M, Hoheisel R, Lehmann C, Haase I, Perniok A, Hallek M, Rubbert A. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 2010, 29:1169-1173. 10.1007/s10067-010-1504-5, 20532937.
    • (2010) Clin Rheumatol , vol.29 , pp. 1169-1173
    • Jung, N.1    Hellmann, M.2    Hoheisel, R.3    Lehmann, C.4    Haase, I.5    Perniok, A.6    Hallek, M.7    Rubbert, A.8
  • 45
    • 84855974706 scopus 로고    scopus 로고
    • Biologic agents for treating ankylosing spondylitis: beyond TNFα antagonists
    • 10.1016/j.jbspin.2011.05.023, 21803631
    • Wendling D, Prati C. Biologic agents for treating ankylosing spondylitis: beyond TNFα antagonists. Joint Bone Spine 2011, 78:542-544. 10.1016/j.jbspin.2011.05.023, 21803631.
    • (2011) Joint Bone Spine , vol.78 , pp. 542-544
    • Wendling, D.1    Prati, C.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.